Latest & greatest articles for migraine

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on migraine or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on migraine and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for migraine

1. Toxins for Health? Botulinum toxin for migraine

Toxins for Health? Botulinum toxin for migraine Tools for Practice is proudly sponsored by the Alberta College of Family Physicians (ACFP). ACFP is a provincial, professional voluntary organization, representing more than 4,800 family physicians, family medicine residents, and medical students in Alberta. Established over sixty years ago, the ACFP strives for excellence in family practice through advocacy, continuing medical education and primary care research. www.acfp.ca May 13, 2019 Toxins (...) for Health? Botulinum toxin for migraine. Clinical Question: What is the efficacy of botulinum toxin for migraine prophylaxis? Bottom Line: Patients with chronic migraine who receive botulinum toxin (example Botox™) have 2 fewer migraine days per month compared to placebo (from 19 days to 11 days with treatment versus 13 days with placebo), with no benefit in episodic migraine. Adverse events include blepharoptosis, muscle weakness, neck/injection site pain and 3% stop treatment due to adverse events

2019 Tools for Practice

2. Erenumab (Aimovig) - for the prophylaxis of migraine

Erenumab (Aimovig) - for the prophylaxis of migraine 1 Published 08 April 2019 1 SMC2134 erenumab 70mg solution for injection in pre-filled pen (Aimovig®) Novartis Pharmaceuticals UK Ltd 8 March 2019 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHSScotland. The advice is summarised as follows: ADVICE: following a full submission erenumab (Aimovig ® ) is accepted (...) for restricted use within NHSScotland. Indication under review: for the prophylaxis of migraine in adults who have at least four migraine days per month. SMC restriction: patients with chronic migraine and in whom at least three prior prophylactic treatments have failed. In studies in patients with episodic and chronic migraine, erenumab significantly reduced the number of migraine days per month compared with placebo. This SMC advice takes account of the benefits of a Patient Access Scheme (PAS

2019 Scottish Medicines Consortium

3. Fremanezumab (Ajovy) - migraine

Fremanezumab (Ajovy) - migraine Official address Domenico Scarlattilaan 6 ? 1083 HS Amsterdam ? The Netherlands An agency of the European Union Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us Send us a question Go to www.ema.europa.eu/contact Telephone +31 (0)88 781 6000 © European Medicines Agency, 2019. Reproduction is authorised provided the source is acknowledged. EMA/107467/2019 EMEA/H/C/004833 Ajovy (fremanezumab) An overview of Ajovy and why it is authorised (...) in the EU What is Ajovy and what is it used for? Ajovy is a medicine used to prevent migraine in adults who have migraines at least 4 days a month. The active substance contained in Ajovy is fremanezumab. How is Ajovy used? Ajovy is injected under the skin using a pre-filled syringe. Patients can inject the medicine themselves after being trained. The recommended dose is either 225 mg every month or 675 mg every three months. For the 675 mg dose, three injections of 225 mg have to be injected one after

2019 European Medicines Agency - EPARs

4. Acupuncture for migraine headaches

Acupuncture for migraine headaches Acupuncture for migraine headaches Toggle navigation Shared more. Cited more. Safe forever. Toggle navigation View Item JavaScript is disabled for your browser. Some features of this site may not work without it. Search MOspace This Collection Browse Statistics Acupuncture for migraine headaches View/ Open Date 2010-04 Format Metadata Abstract Acupuncture reduces the frequency of migraine headaches when used as an adjunct to, or in place of, medical management

2019 Clinical Inquiries

5. Acupuncture shows promise for preventing episodic migraines

Acupuncture shows promise for preventing episodic migraines Acupuncture shows promise for preventing episodic migraines Discover Portal Discover Portal Acupuncture shows promise for preventing episodic migraines Published on 18 October 2016 doi: Acupuncture was about as effective as long term medication in reducing the number of migraines. There were fewer adverse events amongst people receiving acupuncture (16-17%) compared to drug treatment (34%). Migraines affect around one in seven people (...) to people living in certain areas or who can afford to pay for treatment themselves. Share your views on the research. Why was this study needed? Migraines are common, affecting around one in five women and one in 15 men. Symptoms include headache, visual disturbances and nausea, which can be severe enough to stop people living their normal daily life. Migraine attacks last anywhere between four and 72 hours and are estimated to cost the UK economy as much as £2 billion a year in lost work. The cause

2019 NIHR Dissemination Centre

6. “Triptans” can relieve migraines in children and adolescents

“Triptans” can relieve migraines in children and adolescents “Triptans” can relieve migraines in children and adolescents Discover Portal Discover Portal “Triptans” can relieve migraines in children and adolescents Published on 13 September 2016 doi: Triptans, a migraine medication, relieve migraine headache completely within two hours compared to placebo. Ibuprofen was also effective but less well studied. This review was also reassuring in that any side effects of treatment were mild. Most (...) evidence identified in this Cochrane review was for sumatriptan, a commonly prescribed treatment for adults, compared to placebo or dummy pills. A few studies examined other triptans or other painkillers, such as ibuprofen or paracetamol against placebo in children and adults. The findings support current guideline recommendations to prescribe nasal triptans for migraine in adolescents. Only nasal preparations are currently licensed for adolescents, whereas oral administration and use for children

2019 NIHR Dissemination Centre

7. A Randomized Trial of a Long-Acting Depot Corticosteroid Versus Dexamethasone to Prevent Headache Recurrence Among Patients With Acute Migraine Who Are Discharged From an Emergency Department

A Randomized Trial of a Long-Acting Depot Corticosteroid Versus Dexamethasone to Prevent Headache Recurrence Among Patients With Acute Migraine Who Are Discharged From an Emergency Department Migraine patients continue to report headache during the days and weeks after emergency department (ED) discharge. Dexamethasone is an evidence-based treatment of acute migraine that decreases the frequency of moderate or severe headache within 72 hours of ED discharge. We hypothesize that intramuscular (...) with moderate or severe migraine. Outcomes were assessed by telephone with a standardized instrument. The primary outcome was number of days with headache during the week after ED discharge. Secondary outcomes were complete freedom from headache, without the necessity of additional headache medication for the entire week after ED discharge, and medication preference, as determined by asking the patient whether he or she would want to receive the same medication again.One hundred nine patients received

2019 EvidenceUpdates

8. Erenumab (Aimovig) - for the prevention of migraine

Erenumab (Aimovig) - for the prevention of migraine Search Page - Drug and Health Product Register Language selection Search and menus Search Search website Search Topics menu You are here: Summary Basis of Decision - - Health Canada Expand all Summary Basis of Decision (SBD) for Contact: Summary Basis of Decision (SBD) documents provide information related to the original authorization of a product. The for is located below. Recent Activity for SBDs written for approved after September 1, 2012

2019 Health Canada - Drug and Health Product Register

9. Chinese herbal medicine as prophylaxis treatment for episodic migraine in adults: a systematic review and meta-analysis

Chinese herbal medicine as prophylaxis treatment for episodic migraine in adults: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any

2019 PROSPERO

10. Acupuncture methods for acute migraine attack: a Bayesian network meta-analysis

Acupuncture methods for acute migraine attack: a Bayesian network meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email

2019 PROSPERO

11. Treatment of migraine in patients with CADASIL: protocol for a systematic review

Treatment of migraine in patients with CADASIL: protocol for a systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email

2019 PROSPERO

12. The functional alterations in primary migraine: a systematic review and meta-analysis

The functional alterations in primary migraine: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites

2019 PROSPERO

13. Systematic review and meta-analysis of correlation of body magnesium levels and migraine

Systematic review and meta-analysis of correlation of body magnesium levels and migraine Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites

2019 PROSPERO

14. Association between migraine disorders and benign paroxysmal positional vertigo: a meta-analysis

Association between migraine disorders and benign paroxysmal positional vertigo: a meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external

2019 PROSPERO

15. Galcanezumab for preventive treatment of migraine: a systematic review and meta-analysis of efficacy and safety

Galcanezumab for preventive treatment of migraine: a systematic review and meta-analysis of efficacy and safety Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files

2019 PROSPERO

16. Can physical testing be used to distinguish between migraine and cervicogenic headache sufferers? A protocol for systematic review

Can physical testing be used to distinguish between migraine and cervicogenic headache sufferers? A protocol for systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record

2019 PROSPERO

17. Coenzyme Q10 supplementation for prophylaxis in patients with migraine

Coenzyme Q10 supplementation for prophylaxis in patients with migraine Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation

2019 PROSPERO

18. Efficacy and safety of nutritional supplements in migraine

Efficacy and safety of nutritional supplements in migraine Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr

2019 PROSPERO

19. Network meta-analysis of Chinese patent medicine for migraine

Network meta-analysis of Chinese patent medicine for migraine Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr

2019 PROSPERO

20. Pharmacological medications for preventive treatment of migraine: a systematic review and meta-analysis of efficacy and safety

Pharmacological medications for preventive treatment of migraine: a systematic review and meta-analysis of efficacy and safety Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any

2019 PROSPERO